Drug
Maribavir clinical trials
Also written TAK-620 and SHP620.
- studies test it
- 18
- open now
- 3
- in phase 3
- 8
- first study started
- 2004
Keep track of what changes. Save the maribavir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2012 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 3
- Phase 3
- 8
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 3
Shire (9) · Takeda (5) · Medical University of South Carolina (1) · Glaxo Wellcome (1) · Ruijin Hospital (1) · Seoul National University Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses maribavir is read from its arms, and is right about nine times in ten.
Testing it · 18
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)RecruitingPhase 3TakedaNCT05319353Written as Maribavir
- Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCTRecruitingPhase 3Ruijin HospitalNCT07511127Written as Maribavir
- Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific AntibodiesRecruitingPhase 2Seoul National University HospitalNCT07014319Written as Maribavir
- A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) InfectionsCompletedPhase 3TakedaNCT06439342Written as Maribavir
- Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant RecipientsCompletedPhase 4Medical University of South CarolinaNCT06034925Written as Maribavir
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese ParticipantsCompletedPhase 1ShireNCT04497883Written as Maribavir (400 mg)
- A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult ParticipantsTerminatedPhase 1ShireNCT04131556Written as Maribavir
- A Study of Maribavir Pediatric Formulation in Healthy Adult ParticipantsCompletedPhase 1TakedaNCT05918822Written as Maribavir Commercial Tablet Formulation
- A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) InfectionCompletedPhase 3TakedaNCT05137717Written as Maribavir
- Maribavir Food-Effect Study in Healthy Adults ParticipantsCompletedPhase 1TakedaNCT05382104Written as Maribavir
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell TransplantsCompletedPhase 3ShireNCT02927067Written as Maribavir
- Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or CidofovirCompletedPhase 3ShireNCT02931539Written as Maribavir
- Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant RecipientsCompletedPhase 3ShireNCT00497796Written as maribavir
- Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant RecipientsCompletedPhase 3ShireNCT00411645Written as maribavir
- Study of SHP620 (Maribavir) in Healthy AdultsCompletedPhase 1ShireNCT02775240Written as Maribavir
- Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant RecipientsCompletedPhase 2ShireNCT01611974Written as Maribavir
- Maribavir for Prevention of CMV After Stem Cell TransplantsCompletedPhase 2ShireNCT00223925Written as Maribavir
- The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected PatientsCompletedPhase 1Glaxo WellcomeNCT00002373Written as Maribavir
Codes
What other systems call maribavir · ClinicalTrials.gg INT004190
- MeSH (NLM) C400401maribavirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) PTB4X93HE1MARIBAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 2586068One source FDA
- Wikidata Q6762512maribavirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82254MaribavirOne source FDA
- DrugBank DB06234One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C400401 | maribavir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | PTB4X93HE1 | MARIBAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2586068 | — | One source FDA |
| Wikidata | Q6762512 | maribavir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82254 | Maribavir | One source FDA |
| DrugBank | DB06234 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.